Free Shipping on All Orders $75 Or More!

Your Trusted Brand for Over 35 Years

Life Extension Magazine

<< Back to May 2004

A Comprehensive Guide to Preventive Blood Testing

May 2004

By Penny Baron


1. ADVANCEDATA, from Vital & Health Statistics of The National Center for Health Statistics, US Department of Health and Education Welfare, No. 5, February 22, 1977, Public Health Service- Health Resources Administration. “A Comparison of Levels of Serum Cholesterol of Adults 18-74 Years of Age in the Untied States in 1960-62 and 1971- 74.”

2. Mahanonda N, Leowattana W, Kangkagate C, Lolekha P, Pokum S.Homocysteine and restenosis after percutaneous coronary intervention. J Med Assoc Thai.2001 Dec;84 Suppl 3:S636-44.

3. Robinson K, Mayer EL, Miller DP, et al. Hyperhomocysteinemia and low pyridoxal phosphate. Common and inde- pendent reversible risk factors for coronary artery disease. Circulation. 1995 Nov 15;92(10):2825-30.

4. Tenover JS. Effects of testosterone supple- mentation in the aging male. J Clin Endocrinol Metab. 1992 Oct;75(4):1092-8.

5. Phillips GB, Pinkernell BH, Jing TY. The association of hypotestosteronemia with coronary artery disease in men. Arterioscler Thromb. 1994 May;14(5):701-6.

6. Gelfand MM, Wiita B. Androgen and estrogen-androgen hormone replacement therapy: a review of the safety literature, 1941 to 1996. Clin Ther. 1997 May-Jun;19(3):383-404; discussion 367-8.

7. Gooren LJ Endocrine aspects of ageing in the male. Mol Cell Endocrinol. 1998 Oct 25;145(1-2):153-9.

8. Barrett-Connor E, Von Muhlen DG, Kritz- Silverstein D. Bioavailable testosterone and depressed mood in older men: the Rancho Bernardo Study. J Clin Endocrinol Metab. 1999 Feb;84(2):573- 7.

9. Schweiger U, Deuschle M, Weber B, et al. Testosterone, gonadotropin, and cortisol secretion in male patients with major depression. Psychosom Med. 1999 May- Jun;61(3):292-6.

10. Rabkin JG; Wagner GJ; Rabkin R. Testosterone therapy for human immuno-deficiency virus-positive men with and with out hypogonadism. J Clin Psychopharmacol. 1999 Feb;19(1):19-27.

11. Seidman SN, Walsh BT. Testosterone and depression in aging men. Am J Geriatr Psychiatry. 1999 Winter;7(1):18-33.

12. The Testosterone Syndrome, Eugene Shippen and Fryer, W. P. 116.

13. Maximize Your Vitality & Potency, Jonathan Wright and Lenard, L., pp. 146- 47.

14. Super T, Karlis Ullis, MD, Shackman, J, and Ptacek, G. pp. 43-44.

15. Tan RS, Pu SJ. The andropause and memo- ry loss: is there a link between androgen decline and dementia in the aging male? Asian J Androl. 2001 Sep;3(3):169-74.

16. Vanderpump MP, Tunbridge WM, French JM, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf). 1995 Jul;43(1):55-68.

17. Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC. Subclinical hypothyroidism is an independent risk fac- tor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann Intern Med. 2000 Feb 15;132(4):270-8.

18. Michalopoulou G, Alevizaki M, Piperingos G, et al. High serum cholesterol levels in persons with “high-normal” TSH levels: should one extend the definition of subclin- ical hypothyroidism? Eur J Endocrinol. 1998 Feb;138(2):141-45.

19. Pollock MA, Sturrock A, Marshall K, et al. Thyroxine treatment in patients with symp- toms of hypothyroidism but thyroid func- tion tests within the reference range: ran- domized double blind placebo controlled crossover trial. BMJ. 2001 Oct 20;323(7318):891-5.

20. Bjelland I, Tell GS, Vollset SE, Refsum H, Ueland PM. Folate, vitamin B12, homocysteine, and the MTHFR 677CT polymorphism in anxiety and depression. The Hordaland Homocysteine Study. Archives of General Psychiatry. 2003 Jun;60(6):618-26.

21. Koenig W, Sund M, Fröhlich M, et al. C- reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men. Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 1999 Jan 19;99(2):237-42

22. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridket PM. C-reactive protein, interleukin 6, and risk of developing Type II diabetes mellitus. JAMA. 2001 Jul 18;286(3):327-34.

23. Teunissen CE, van Boxel MP, Bosma H, et al. Inflammation markers in relation to cog- nition in a healthy aging population. J Neuroimmunol. 2003 Jan (1-2);134:142-50.

24. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovas- cular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003 Jan 28;107(3):499-511.

25. Catalona WJ, Partin AW, Slawin KM, et al. Use of percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic dis- ease. A prospective multicenter clinical trial. JAMA. 1998 May 20; 279(19):1542-7.

26. Punglia RS, D’Amico AV, Catalona WJ, Roehl KA, Karen M., Kuntz KM. Effect of verification bias on screening for prostate cancer by measurement of prostate- specific antigen. N Engl J Med. 2003 Jul 24;349(4):335-42.

27. Reuters Health: Precursor of PSA accurate ly detects prostate cancer. July 15, 2003.

28. Reuters Health: Exercise tougher at begin ning of menstrual cycle. July 5, 2002.

29. Dinarello CA. Proinflammatory cytokines. Chest. 2000;118:503-508. 30. Kiecolt-Glaser JK, Preacher KJ, MacCallum RC, Atkinson C, Malarkey WB, Glaser R. Chronic stress and age-related increases in the proinflammatory cytokine IL-6. Proc Natl Acad Sci. 2003 Jul 22;100(15):9090-5.

31. Verdecchia P, Reboldi G, Porcellati C, et al. Risk of cardiovas cular disease in relation to achieved office and ambulatory blood pres- sure control in treated hypertensive sub- jects. J Am Coll Cardiol. 2002 Mar 6;39(5):878-85.

32. Mendall MA, Patel P, Asante M, et al. Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease. Heart. 1997 Sep;78(3):273-7.

33. Lappe JM, Muhlestein JB, Carlquist JF, Davis BF, Horne BD, Anderson JL. Inlerleukin-1 beta predicts death or myocardial infarction independently of high-sensitivity C-reactive protein and stan- dard risk factors in patients with coronary artery disease. Abstracts – Myocardial Ischemia and Infarction 841-2. J Am Coll Cardiol. 2002.

34. Brambilla F, Bellodi L, Perna G, Bertani A, Panerai A, Sacerdote P. Plasma Interleukin-1beta concentrations in panic disorder. Psychiatry Res. 1994 Nov;54(2):135-42.

35. Ishimi Y, Miyaura C, Jin CH, Akatsu T, Abe E, Nakamura Y, Yamaguchi A, Yoshiki S, Matsuda T, Hirano T, et al. IL-6 is pro- duced by osteoblasts and induces bone resorption. J Immunol. 1990 Nov 15;145(10):3297-303.

36. Lou W, Ni Z, Dyer K, Tweardy DJ, Gao AC. Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway. Prostate. 2000 Feb 15;42(3):239-42.

37. Harris TB, Ferrucci L, Tracy RP, et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med. 1999 May;106(5):506-12.

38. Cappola AR, Xue Q-L, Ferrucci L, Guralnik JM, Volpato S, Fried LP. Insulin- like growth factor I and interleukin-6 con- tribute synergistically to disability and mor- tality in older women. J Clin Endocrinol Metab. 2003 May;88(5):2019-25.

39. Ferruci L, Harris TB, Guralnik JM, et al. Serum IL-6 level and the development of disability in older persons. J Am Geriatr Soc. 1999 Jun;47(6):639-46.

40. Radack K, Deck C, Huster G. Dietary sup- plementation with low-dose fish oils lowers fibrinogen levels. Ann Intern Med. 1989 Nov 1;111(9):757-8.

41. Folsom AR, Wu KK, Shahar E, Davis CE. Association of hemostatic variables with prevalent cardiovascular disease and asymp- tomatic carotid artery atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Arterioscler Thromb. 1993 Dec;13(12):1829-36.

42. Kyrle PA, Minar E, Hirschl M, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med.2000 Aug 17;343(7):457-62. 43. Walston J, McBurnie MA, Newman A, et al. Frailty and activation of the inflamma tion and coagulation systems with and with out clinical comorbidities. Arch Intern Med. 2002 Nov 11;162(20):2333-41. 44. Burguera JL, Burguera M, Gallignani M, Alarcon OM, Burgueera JA. Blood serum selenium in the province of Merida, Venezuela, related to sex, cancer incidence and soil selenium content. J Trace Elem Electrolytes Health Dis. 1990 Jun;4(2):73-7.

45. Mukoyama M, Nakao K, Hosoda K, et al. Brain natriuretic peptide as a novel cardiac hormone in humans: evidence for an exqui site dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest. 1991 Apr:87(4):1402-12.

46. Carillo-Jimenez R, Treadwell TL, Goldfine H, Buenano A, Lamas GA, Hennekens CH. Brain natriuretic peptide and HIV-related cardiomyopathy. AIDS Read. 2002 Nov;12(11):501-8.

47. Kawai K, Hata K, Takaoka H, Kawai H, Yokoyama M. Plasma brain natriuretic pep- tide as a novel therapeutic indicator in idio- pathic dilated cardiomyopathy during beta- blocker therapy: a potential of hormone- guided treatment. Am Heart J. 2001 Jun;141(6):925-32.

48. Richards AM, Nicholls MG, Yandle TG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neuro- hormonal predictors of left ventricular func- tion and prognosis after myocardial infarc- tion. Circulation. 1998 May 19;97(19):1921- 9.

49. Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol. 2001 Feb;37(2):379-85.

50. Available at: shot /2001_02.html#hpfi. Accessed March 10, 2004.

51. Cheng-Lai A, Levine A. Rosiglitazone: an agent from the thiazolidinedione class for the treatment of type 2 diabetes. Heart Dis. 2000 Jul-Aug;2(4):326-33.

52. Krentz AJ, Bailey CJ, Melander A. Thiazolidinediones for type 2 diabetes. BMJ. 2000 Jul 29;321(7256):252-3.

53. Ogawa S, Takeuchi K, Ito S. Plasma BNP levels in the treatment of type 2 diabetes with piglitazone. J Clin Endocrinol Metab. 2003 Aug;88(8):3993-6.

54. Burguera JL, Burguera M, Gallignani M, Alarcon OM, Burgueera JA. Blood serum selenium in the province of Merida, Venezuela, related to sex, cancer incidence and soil selenium content. J Trace Elem Electrolytes Health Dis. 1990 Jun;4(2):73-7.

55. Fleet JC. Dietary selenium repletion may reduce cancer incidence in people at high risk who live in areas with low soil selenium. Nutr Rev. 1997 Jul;55(7):277-9.

56. Knekt P, Marniemi J, Teppo L, Heliovaara M, Aromaa A. Is low selenium status a risk factor for lung cancer? Am J Epidemiol. 1998 Nov 15;148(10):975-82.

57. Patterson BH, Levander OA. Naturally occurring selenium compounds in cancer chemoprevention trials: A workshop sum- mary. Cancer Epidemiol Prev. 1997 Jan;6(1):63-9.

58. Russo MW, Murray SC, Wurzelmann JI, Woosley JT, Sandler RS. Plasma selenium levels and the risk of colorectal adenomas. Nutr Cancer. 1997 ;28(2):125-9.

59. Shamberger RJ. The genotoxicity of seleni- um. Mutat Res.1985 Jul;154(1):29-48.

60. Young KJ, Lee PN. Intervention studies on cancer. Eur J Cancer Prev. 1999 Apr;8(2):91-103.

61. Fleet JC. Dietary selenium repletion may reduce cancer incidence in people at high risk who live in areas with low soil selenium. Nutr Rev. 1997 Jul;55(7):277-9.

62. Bonora E, Kiechl S, Willeit J, et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes. 1998 Oct;47(10):1643-9.

63. Arad Y, Newstein D, Cadet F, Roth M, Guerci AD. Association of multiple risk factors and insulin resistance with increased prevalence of asymptomatic coronary artery disease by an electon-beam computed tomographic study. Arterioscler Thromb Vasc Biol. 2001 Dec;21(12):2051-8.

64. Bonora E, Formentini G, Calcaterra F, et al. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in Type II diabetic subjects. Prospective data from the Verona Diabetes Complications Study. Diabetes Care. 2002 Jul;25(7):1135-41.

65. Available at: media/pcc020916/sciInsulinResistant.html. Accessed March 10, 2004.

66. Barton-Davis ER, Shoturma DI, Musaro A, Rosenthal N, Sweeney HL. Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function. Proc Natl Acad Sci. 1998 Dec 22;95(26):15603-7.

67. Ruiz-Torres A, Soares de Meo Kirzner M. Ageing and longevity are related to growth hormone/insulin-like growth factor-1 secre- tion. Gerontology. 2002 Nov-Dec;48(6);401- 7.

68. van den Beld AW, Bots ML, Janssen JA, Pols HA, Lamberts SW, Grobbee DE. Endogenous hormones and carotid atherosclerosis in elderly men. Am J Epidemiol. 2004 Jan 1;157(1):25-31.

69. Carro E, Trejo JL, Gomez-Isla T, LeRoith D, Torres-Aleman I. Serum insulin-like growth factor I regulates brain amyloid-B levels. Nature Medicine. 2002 Dec;8(12):1390-7.

70. Woodson K, Tangrea JA, Pollak M, et al. Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. Cancer Res. 2003 Jul 15;63(14):3991-4.

71. Wilczak N, de Vos RAI, De Keyser J. Free insulin-like growth factor (IGF)-1 and IGF binding proteins 2,5, and 6 in spinal motor neurons in amyotrophic lateral sclerosis. Lancet. 2003 Mar 22;361(9362):1007-11.

72. Di Marzio L, Moretti S, D’Alo S, et al. Acetyl-L-carnitine administration increases insulin-like growth factor 1 levels in asymp- tomatic HIV-1-infected subjects: correlation with its suppressive effect on lymphocyte apoptosis and ceramide generation. Clin Immunol. 1999 Jul;92(1):103-10.

73. Ladenson PW, Singer PA, Ain KB, et al. American Thyroid Association guidelines for detection of thyroid dysfunction. Arch Intern Med. 2000 Jun 12;160(11):1573-5.

74. Vanderpump MP, Tunbridge WM, French JM et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol. 1995 Jul;43(1):55-68.

75. Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC. Subclinical hypothyroidism is an independ- ent risk factor for atherosclerosis and myocardial infarction in elderly women: The Rotterdam Study. Ann Intern Med. 2000 Feb 15;132(4):270-8.

76. Michalopoulou G, Alevizaki M, Piperingos G. et al. High serum cholesterol levels in persons with “high-normal” TSH levels: should one extend the definition of subclini- cal hypothyroidism. Eur J Endocrinol. 1998 Feb;138(2):141-5.

77. Garnero P, Hausherr E, Chapey MC, et al. Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study. J Bone Min Res. 1996 Oct;11(10):1531-8.

78. Hesley RP, Shepard KA, Jankins DK, Riggs BL. Monitoring estrogen replacement ther- apy and identifying rapid bone losers with an immunoassay for deoxypyridinoline. Osteoporos Int.1998;8(2):159-64.

79. Scheidt-Nave C, Bismar H, Leidig-Bruckner G, et al. Serum inter- leukin 6 is a major predictor of bone loss in women specific to the first decade past menopause. J Clin Endocrinol Metab. 2001 May;86(5):2032-42.

80. Lakatos P, Foldes J, Horvath C, et al. Serum interleukin-6 and bone metabolism in patients with thyroid function disorders. J Clin Endocrinol Metab. 1997 Jan;82(1):78-81.